Blackstone Minerals (BSX:AU) has announced Managing Director Resignation and Board Changes
Download the PDF here.
This post appeared first on investingnews.com
Jeffrey Christian, managing partner at CPM Group, shares his outlook for gold and silver in 2026, explaining why he expects higher prices for the metals.
‘We think that 2026 is going to be a more hostile environment than 2025, and that will cause investors to buy more gold and silver. So we’re expecting gold and silver prices to spike higher than they are today at times during 2026,’ he explained.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Don Durrett: Gold, Silver Price Targets and 15 ‘Must-Own’ Silver Stocks
Kicking off the list in the fifth spot is Don Durrett of GoldStockData.com.
In this January interview, Don shared his silver and gold price outlook for 2025, as well as his 15 ‘must-own’ silver stocks. We don’t have time here for the full list, but I’ll leave the link to the video below. For now, here’s Don talking about why he’s so bullish on silver and gold stocks.
Peter Grandich: Gold Mines Set to Print Cash as Price Hits New Highs
Peter Grandich of Peter Grandich & Co. is next.
This interview is from all the way back in February, when gold was still around US$2,800 per ounce. Peter talked about how US$5,000 was no longer sounding outlandish to him, and also explained how the higher gold price could impact mining companies.
Vince Lanci: Silver’s London Liquidity Crisis — What’s Happening, What’s Next
Vince Lanci of Echobay Partners is always a popular guest, and in mid-October he helped break down unusual dynamics in silver, which had broken through US$50 per ounce.
Ed Steer: Silver Rally Now Unstoppable, Price to Hit Triple Digits
Ed Steer of Ed Steer’s Gold and Silver Digest comes in at number two. This interview is also from mid-October, and in it Ed weighed in on the silver market’s complex inner workings. Ed also gave his thoughts on the precious metal’s long-term prospects.
Rick Rule: Gold Strategy, Oil Stocks I Own, ‘Sure Money’ in Uranium
Finally, our most popular interview of 2025 was with none other than Rick Rule of Rule Investment Media. In this early November conversation, he said he had recently sold 25 percent of his junior gold stocks; he also explained why he did it and how he redeployed that capital.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
The holiday season brings more than festive cheer, as for investors, it may signal the start of the so-called Santa Claus rally.
The Santa Claus rally is a period between the final trading days of December and the first days of January when stocks tend to climb. While this seasonal uptick isn’t guaranteed, historical data shows that markets rise more often than not during this window, driven by investor optimism, low trading volumes and year-end portfolio adjustments.
Historically, the last five trading days of December and the first two of January have been a period of above-average stock gains, offering a short, sharp rally for markets heading into the new year.
According to the Stock Trader’s Almanac, the Santa Claus rally has delivered an average gain of 1.3 percent for the S&P 500 (INDEXSP:.INX) since 1950. The phenomenon was first documented in 1972 by Yale Hirsch, founder of the Almanac, and continues to shape investor expectations today.
As for whether 2025 will deliver a Santa Claus rally to close out the year, after a choppy first half for December, markets have shown signs that a late-year recovery is possible.
When does the Santa Claus rally start?
The Santa Claus rally typically occurs over the final five trading days of December and the first two trading days of January. For 2025, the rally window begins on Wednesday, December 24, and runs through Monday, January 5, if historical patterns hold.
This narrow window often yields modest, yet consistent, returns for investors who time the market correctly.
While the rally’s timeframe is traditionally short, its effects can ripple through the market into early January. Essentially, a strong performance during this period can set the tone for January.
However, the exact timing of the Santa Claus rally can vary. Some analysts suggest that the rally has started earlier in recent years as investors attempt to front run the effect by increasing their positions in mid-December. This shift may blur the lines between the Santa Claus rally and broader December market upswings.
Will 2025 deliver a Santa Claus Rally?
This year, the S&P 500 fell during the middle of the month following a cooler-than-expected, albeit controversial, inflation report, which raised hopes for additional interest-rate cuts next year.
Despite this downturn, analysts note that a weak start to December has often failed to derail Santa’s run. Since 1950, the S&P 500 finished the Santa Claus rally period higher in 77 percent of years, even after early-month declines. By the end of the week, the index had already regained some ground, and it continued higher in the days leading up to Christmas.
“Barring any major shocks, it will be hard to fight the overwhelmingly positive seasonal period we are entering and the cleaner positioning set-up,” Goldman Sachs’ (NYSE:GS) trading desk team wrote in a note to clients, as reported by Bloomberg. ‘While we don’t necessarily see a dramatic rally, we do think there is room to go up from here into year end.”
Jeffrey Hirsch, editor-in-chief of the Stock Trader’s Almanac and Yale Hirsch’s son, also weighed in on the markets.
“It looks like (the Santa Claus rally) is set up and we can make another high by the end of the year,” he told MarketWatch. Hirsch cited cooler inflation readings and slower job growth in November, which may give the Federal Reserve room to cut interest rates in 2026.
It remains to be seen whether these predictions will come true, or if the market will be weighed down by factors including recent volatility in technology and artificial-intelligence-linked stocks.
Is the Santa Claus rally reliable?
Despite skepticism in some quarters, historical data supports the existence of the Santa Claus rally, and it is well documented.
Historically, the Santa Claus rally has been a relatively consistent period of gains. That said, historical patterns do not guarantee results, and not every year delivers the expected results. The S&P 500 lost about half a percentage point during the Santa rally period in 2024, and consecutive losses are rare but possible.
Columnist Mark Hulbert has expressed skepticism about the event in the past, noting that there is no definitive evidence that the market consistently outperforms during this period.
“An analysis of the past century reveals that the stock market in the weeks prior to Christmas is no more likely to rally than at other times of the year. (I suggest investors) ignore any arguments based on an alleged Santa Claus Rally,” Hulbert warned in an opinion piece posted on MarketWatch in 2018.
In 2019, for example, the market experienced volatility in December, defying the usual pattern.
In a December 2025 interview with CNBC, Jeffrey Hirsch cautioned that failure to rally is not an immediate bear-market signal, but rather “a flag to start looking at the other data — whether it’s seasonal indicators or other fundamental or technical measures.”
Despite the varying takes, many investors view the rally as a psychological phenomenon — one that influences market sentiment even if the returns are marginal.
Strategies for the Santa Claus rally
Now that the Santa Claus rally seems to be underway, investors interested in joining in have a variety of options, including domestic markets, international diversification or targeted sector plays such as mega-cap tech stocks.
As always, consulting with a financial advisor and conducting thorough research remains essential. While the Santa Claus rally offers potential rewards, market conditions can shift quickly, making flexibility and prudence key to success.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for a continued recovery, driven in part by the integration of artificial intelligence (AI).
However, this sectoral resurgence must navigate a tug-of-war between supportive stimulus and structural risks, which have the potential to challenge the pace of recovery.
Biotech sector rebounding after US uncertainty
According to Song, biotech has rebounded since its lows in April of this year.
Company valuations are trading at a 15 percent discount to broader markets on forward price-to-earnings, with secular demand intact for oncology, obesity and chronic diseases. In Song’s view, the biotech industry’s rebound stems from reduced uncertainty under the administration of US President Donald Trump.
Song added that valuations across healthcare are reasonable, noting rotational flows from cooling AI hype.
“I can’t deny that there have been some rotational effects that not just biotech has benefited (from), but healthcare in general,’ he commented. “While AI is an important driver in healthcare, to our view, it certainly is not priced in to the largest extent in many pockets of healthcare.”
Key biotech sector catalysts in 2026
Song sees healthcare’s recovery extending into 2026, with oncology remaining the primary growth engine.
He characterized the current sector resurgence as a durable structural shift being fueled by key developments that present tangible investment opportunities, including anticipated positive clinical trial outcomes, such as those for Revolution Medicines’ (NASDAQ:RVMD) pancreatic cancer drug.
“They have a lead drug that blocks an important pathway called RAS … and they could have a potential breakthrough in pancreatic cancer. They’re running a Phase III trial to demonstrate a potential survival benefit. There could be meaningful progress there,” Song noted. A data readout is expected next year.
Outside oncology, Song flagged high-profile biotech catalysts that could broaden the sector’s 2026 rally.
“Non-peptide oral GLP-1s … are clearly going to be an important data set readout and launch that could occur next year,” he explained, citing Eli Lilly’s (NYSE:LLY) orforglipron, a daily pill that hit Phase III success for type 2 diabetes and obesity in 2025. Approval is expected in 2026, and he believes it could be a potential game changer in obesity and chronic disease treatments, an area dominated by biotech innovators.
Song also sees validation ahead for platform technologies.
A dual-track recovery for biotech
While macro analysts see a broad cyclical recovery in 2026, Song predicts that the market will be defined by a dual-track recovery: a diagnostics-led initial public offering (IPO) surge, and a biopharma M&A environment focused on companies with the clinical validation required to alter the current standard of care.
Renaissance Capital predicts a faster pace for biotech IPOs, with a strong pipeline of companies such as Aktis Oncology, a radiopharma diagnostics firm targeting solid tumors, ready to list for US$100 million.
Additionally, AlphaSense forecasts steady M&A flow as companies rebuild their pipelines in the new year, a trend that Song sees as a structural necessity rather than a simple trend. “It’s an important pillar where Big Pharma needs to replenish their pipelines, and they can’t all do it internally,” he explained.
Consequently, he believes the primary “hunting ground” for these deals is mid-cap territory, where acquiring one or two proven drugs can effectively move the needle for a large pharmaceutical giant.
AI in the biotech sector
Song maintained that AI has not reached full valuation in the sector, and its role is expected to grow, with significant future productivity gains predicted in biopharma, drug discovery, clinical development and healthcare delivery.
“We’ve done some preliminary work that that that suggests there could be … productivity gains in areas like biopharmaceuticals and drug discovery and clinical development,” Song explained, adding that these are long-term projections. He sees a more immediate economic impact in how care is managed.
“Since healthcare is a large part of the US and global economy, and growing quickly in terms of healthcare costs, there are also opportunities for efficiency gains, which could lead to margin and consumer gains,” he noted. This revolution in delivery is already a key focus for his firm’s Tema Oncology ETF (NASDAQ:CANC).
However, life science market analyst Anastasia Bystritskaya warned that valuation and productivity are not synonymous, as high-performing models do not automatically become revenue-producing products. For investors, the real inflection point is operational integration rather than operating as a standalone prototype.
Drive for efficiency is expected to take a practical form in 2026 through what Sergey Jakimov, managing partner at longevity and biotech venture capital firm LongeVC, described as the “doctor in your hand.”
This AI companion manages routine, low-complexity tasks between clinic visits.
LongeVC anticipates that this shift to a regulated digital workflow will allow AI to identify meaningful clinical signals continuously without overburdening primary care teams.
This democratization of discovery creates a new competitive landscape for the hunting ground Song described; if AI-enabled teams can dissect complex pathways without a billion-dollar balance sheet, the traditional R&D model of Big Pharma faces a permanent disruption. In this new era, the innovation gap could be filled by agile players who use technology to act with the scale of a giant, but the speed of a startup.
Investor takeaway
Despite sector momentum, headwinds remain, particularly regarding the stability of clinical research funding.
A November report in JAMA Internal Medicine reveals that 383 clinical trials recently had their grants terminated, disrupting progress for over 74,000 participants. Dr. Gary K. Zammit, founder of Clinilabs, warned these reductions in National Institutes of Health funding risk slowing future commercial development of innovative therapies.
Macroeconomic headwinds, including rising tariffs and early labor market weakness, also present a material challenge.
Ultimately, the 2026 biotech outlook balances promising catalysts with the need for strategic capital deployment and a focus on clinically validated platform technologies, ensuring a durable expansion for the sector.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Craig Hemke, publisher of TFMetalsReport.com, shares his thoughts on the gold and silver markets heading into 2026, outlining why he remains bullish.
‘Just keep adding some — it’s your protection against the madness. It’ll get you through the storm,’ he said. ‘It preserves your net worth from the destruction of these bankers and politicians.’
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Altius Minerals (TSX:ALS,OTCQX:ATUSF) is making a bet on a lithium market recovery, agreeing to acquire Lithium Royalty (TSX:LIRC) in a C$520 million deal that will expand its exposure to battery metals.
Under a definitive agreement announced by the two companies on Monday (December 22), Altius plans to purchase all of the issued common and convertible common shares of Lithium Royalty for C$9.50 each.
The amount will be paid as either C$9.50 in cash or 0.24 of a common Altius share, according to shareholders’ election.
For Altius, the acquisition will allow it to bring a portfolio of 37 lithium royalties into its fold. None of them involve streams, and they span projects from production through early exploration.
Four of the royalties are tied to producing assets, three of which were commissioned in 2025 and are currently ramping up or expanding. Another 12 projects are in advanced stages with completed economic studies, while three to five additional assets are targeting startup between 2026 and 2030.
The company said the portfolio is geographically concentrated in lower-risk jurisdictions, with most assets located in Canada, Australia and South America, and diversified across both brine-based and hard-rock lithium production.
At the current spot price, Altius expects the acquired royalties to contribute between US$29 million and US$43.7 million in annual revenue by the end of the decade. Lithium carbonate equivalent prices fell to multi-year lows in 2025, holding below US$9,000 per metric ton for most of the year, even as demand continues to expand beyond electric vehicles.
Altius said global lithium demand is expected to exceed 1.5 million metric tons of lithium carbonate equivalent in 2025, with supply deficits potentially re-emerging as early as 2026 after years of oversupply.
Altius Chief Executive Brian Dalton said lithium has “emerged as a mainstream scale mined commodity,” and described the acquired portfolio as featuring “very long resource lives,” strong cost positioning and low jurisdictional risk.
A special shareholders’ meeting is scheduled to happen no later than March 10, 2026.
If approved, the deal is expected to close in the first quarter of 2026, after which Lithium Royalty shares will be delisted and the company will cease to be a reporting issuer in Canada.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
(TheNewswire)
Vancouver, British Columbia / December 23, 2025 ‑ TheNewswire – Harvest Gold Corporation (TSXV: HVG,OTC:HVGDF) (‘Harvest Gold‘ or the ‘Company‘) is pleased to announce the completion of its maiden drill program on the northern and central areas of Mosseau, its flagship project in Quebec’s Abitibi Urban Barry belt, the home to Gold Field’s Windfall deposit. Further is a summary of the advancements made on Harvest Gold’s district scale land package in 2025.
Harvest Gold President and CEO, Rick Mark, states: ‘Looking back, it has been a very busy and successful year advancing our three property, district scale land package in the Quebec Urban Barry belt. We could not have done it without the ongoing support of our largest shareholder, Crescat Capital, who now owns approximately 19.9% of Harvest Gold, and all the other investors who participated in our three private placements this year. I also want to recognize Louis Martin, who has led our excellent geological team and managed the various exploration and drilling programs conducted in 2025. We are very much looking forward to 2026’.
MOSSEAU
Harvest Gold completed 21 diamond drill holes totaling 4,692 metres on the Mosseau property. Drilling targeted the northern and central areas of the property. Assay results for the northern drill holes have been received and have either been reported or are currently being compiled. Assay results from the central portion of the property are pending, with complete results from both areas expected in January.
Diamond drilling was carried out by Forage Rouillier Drilling of Amos. Drill supervision and core logging were completed by Explo-Logik, and drill core analyses were performed by AGAT Laboratories.
Additional work on Mosseau completed in 2025 included expanded magnetic coverage flown by Novatem over newly staked claims adjoining the Mosseau Property and a second phase of prospecting and a soil sampling program by IOS.
URBAN BARRY
A regional, property-wide reconnaissance till sampling program was completed by IOS in 2025. Results are pending and are expected in January 2026.
LaBELLE
A property wide high-resolution airborne magnetic survey flown by Novatem was completed over the Labelle property. This survey confirmed the extension of the Kiask River Corridor across the property. A prospecting and soil survey was also completed over the western part of the property. Results are pending and are expected in January 2026.
FINANCING
In 2025, the Company raised a total of $3,429,299.89 in three non-brokered private placements to fund exploration activities on its three properties in Quebec’s Urban Barry belt.
About Harvest Gold Corporation
Harvest Gold is focused on exploring for near-surface gold deposits and copper-gold porphyry deposits in politically stable mining jurisdictions. Harvest Gold’s board of directors, management team and technical advisors have collective geological and financing experience exceeding 400 years.
Harvest Gold has three active gold projects focused in the Urban Barry area, totalling 377 claims covering 20,016.87 ha, located approximately 45-70 km west of Gold Fields Limited’s – Windfall Deposit.
Harvest Gold acknowledges that the Mosseau Gold Project straddles the Eeyou Istchee-James Bay and Abitibi territories. Harvest Gold is committed to developing positive and mutually beneficial relationships based on respect and transparency with local Indigenous communities.
Harvest Gold’s three properties, Mosseau, Urban-Barry and LaBelle, together cover over 50 km of favorable strike along mineralized shear zones.
Qualified Person Statement
All scientific and technical information in this news release has been prepared and approved by Louis Martin, P.Geo., Technical Advisor to the Company and considered a Qualified Person for the purposes of NI 43-101.
ON BEHALF OF THE BOARD OF DIRECTORS
Rick Mark
President and CEO
Harvest Gold Corporation
For more information please contact:
Rick Mark or Jan Urata
@ 604.737.2303 or info@harvestgoldcorp.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information
This news release includes certain statements that may be deemed ‘forward looking statements’. All statements in this news release, other than statements of historical facts, that address events or developments that Harvest Gold expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words ‘expects’, ‘plans’, ‘anticipates’, ‘believes’, ‘intends’, ‘estimates’, ‘projects’, ‘potential’ and similar expressions, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’ or ‘should’ occur.
Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
Copyright (c) 2025 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia
This post appeared first on investingnews.com
Sun Summit Minerals Corp. (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) (‘Sun Summit’ or the ‘Company’) is pleased to announce that it has closed its non-brokered private placement (the ‘Private Placement’) previously announced in the Company’s press releases on December 9, 2025 and December 12, 2025, through the issuance of (i) 67,857,143 charity flow-through common shares in the capital of the Company (each, a ‘Charity FT Share’) at a price of $0.14 per Charity FT Share; and (ii) 20,000,000 non-flow-through common shares in the capital of the Company (each, an ‘NFT Shares’) at a price of $0.10 per NFT Share, for aggregate gross proceeds to the Company of $11,500,000.
The Charity FT Shares qualify as a flow-through share within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the ‘Tax Act‘).
The Company intends to use the gross proceeds of the Private Placement for exploration of the Company’s JD, Theory and Buck properties and any other Canadian properties that the Company may acquire, and for general working capital purposes, provided that the Company will use an amount equal to the gross proceeds received by the Company from the sale of the Charity FT Shares to incur eligible ‘Canadian exploration expenses’ that will qualify as ‘flow-through mining expenditures’ as such terms are defined in the Tax Act.
In connection with the Private Placement, the Company paid aggregate cash finder’s fees of $303,380 and granted an aggregate of 2,944,400 non-transferable finder warrants of the Company (each, a ‘Finder Warrant‘) to arm’s length finders of the Company in connection with the Private Placement. Each Finder Warrant entitles the holder thereof to purchase one Common Share of the Company, at an exercise price of $0.14 per share until December 23, 2027.
The Private Placement is subject to the final approval of the TSX Venture Exchange (the ‘TSXV‘). The securities issued in the Private Placement are subject to a hold period expiring on April 24, 2025, in accordance with applicable securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder.
Options Issuance
The Company also announces that it has, subject to approval of the TSXV, granted an aggregate of 9,000,000 stock options of the Company (the ‘Options‘) to certain employees, directors and advisors of the Company, in accordance with the rules of the TSXV and the Company’s stock option plan. Each Option entitles the holder thereof to acquire one common share in the capital of the Company (each, a ‘Common Share‘) at an exercise price of $0.15 per Common Share until December 23, 2030.
About Sun Summit
Sun Summit Minerals (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) is a mineral exploration company focused on the discovery and advancement of district scale gold and copper assets in British Columbia. The Company’s diverse portfolio includes the JD and Theory Projects in the Toodoggone region of north-central B.C., and the Buck Project in central B.C.
Further details are available at www.sunsummitminerals.com.
On behalf of the board of directors
Niel Marotta
Chief Executive Officer & Director
info@sunsummitminerals.com
For further information, contact:
Matthew Benedetto, Simone Capital
mbenedetto@simonecapital.ca
Tel. 416-817-1226
Forward-Looking Information
Statements contained in this news release that are not historical facts may be forward-looking statements, which involve risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. In addition, the forward-looking statements require management to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the management’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as ‘anticipate’, ‘will’, ‘expect’, ‘may’, ‘continue’, ‘could’, ‘estimate’, ‘forecast’, ‘plan’, ‘potential’ and similar expressions. Forward-looking statements contained in this press release may include, but are not limited to, use of proceeds of the Private Placement; the size and scope of the drill program at the JD property; the Company’s exploration plans and forecasts; and obtaining regulatory approval for the Private Placement, the grant of Options and exploration plans of the Company. These forward-looking statements are based on a number of assumptions which may prove to be incorrect which, without limiting the generality of the following, include: the state of the equity financing markets in Canada and other jurisdictions; the receipt of regulatory approval; the Company’s ability to complete the drill program as currently contemplated; risks inherent in exploration activities; volatility and sensitivity to market prices; volatility and sensitivity to capital market fluctuations; and fluctuations in metal prices. The forward-looking statements contained in this press release are made as of the date hereof or the dates specifically referenced in this press release, where applicable. Except as required by applicable securities laws and regulation, Sun Summit disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278984
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com
Lobo Tiggre, CEO of IndependentSpeculator.com, described uranium’s key role in providing baseload energy, a narrative that is only being heightened by added artificial intelligence data center and electric vehicle (EV) demand projections.
“The use case is baseload power. There’s no substitution, and the world is building like gangbusters,” he explained. “If the EV story completely went away, it wouldn’t undo the thesis for uranium, It would remove a tailwind, not the base story.”
Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com